Aurobindo Pharma gets USFDA nod to make attention deficit disorder drug

Atomoxetine market worth $1.1 bn; Sun Pharma, Intas, Torrent are other makers of generic drug

Aurobindo Pharma has received final approval from the US Food and Drug Administration (USFDA) to manufacture Atomoxetine capsules that are used for the treatment of attention-deficit hyperactivity disorder (ADHD).

"Atomoxetine capsules 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg will be launched immediately," the company said. "The product is AB rated that meets necessary bioequivalence standards, the generic equivalent of Eli Lilly and its Strattera capsules."

ADHD is a neurobiological disorder that affects normal behaviour and impairs the ability to concentrate. Though the ADHD symptoms begin in childhood, it can continue through adolescence and adulthood.

The generic Atomoxetine is manufactured by other companies such as Sun Pharma, Intas and Torrent having brand names Attentrol, Axepta and Tomoxetin, respectively. The type of drug comprises of both tablets and capsules.

Atomoxetine has an estimated market size of $1.1 billion for the twelve months ending March 2017, according to global information services company IMS Health.